Neuroprotective effects of p62(SQSTM1)-engineered lactic acid bacteria in Alzheimer’s disease: a pre-clinical study

Valentina Cecarini, Laura Bonfili, Olee Gogoi, Solomon Lawrence, Franco Maria Venanzi, Vasco Azevedo, Pamela Mancha-Agresti, Mariana Martins Drumond, Giacomo Rossi, Sara Berardi,

Aging · 2020 · 47 citations · 54 references

DOIFull text

Open access

Concepts

Abstract

strain carrying one plasmid (pExu) that contains a eukaryotic expression cassette encoding the human p62 protein. 3xTg-AD mice orally administered with these bacteria for two months showed an increased expression of endogenous p62 in the brain, with a protein delivery mechanism involving both lymphatic vessels and neural terminations, and positive effects on the major AD hallmarks. Mice showed ameliorated memory, modulation of the ubiquitin-proteasome system and autophagy, reduced levels of amyloid peptides, and diminished neuronal oxidative and inflammatory processes. Globally, we demonstrate that these extremely safe, non-pathogenic and non-invasive bacteria used as delivery vehicles for the p62 protein represent an innovative and realistic therapeutic approach in AD.

References

54